Open the map

Abbott LaboratoriesABT

Diagnostics · NYSE · USA

$98.49
Down 0.2% todayClose

Down 21.2% this year but +4.6% since June 26, behind the life science sector at +10.7%. Abbott Laboratories supplies 2 mapped companies.

This year
−21.2%
1 year
−25.8%
P/E
31.0
P/S
3.6
P/B
3.3

Price vs the life science sector

since Jun 26ABTLife science sector, equal weight
Abbott Laboratories (ABT) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. ABT: +4.6% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.0%+10%+20%Jun 26AugSepOct 8ABT +4.6%Sector +10.7% Abbott Laboratories (ABT) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. ABT: +4.6% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.0%+10%+20%Jun 26AugSepOct 8ABT+4.6%Sector+10.7%

Supply chain

2 customers
SUPPLIERS →→ CUSTOMERSNone mappedLabcorp (LH)LHLabcorp+0.7%Quest Diagnostics (DGX)DGXQuest Diagnostics+1.7%ABTAbbott Laborato… Open the full chain →

About Abbott Laboratories

In vitro diagnostics, medical devices that include the Libre glucose sensors, nutrition products and generic medicines: Abbott runs all four.

Theme exposure

DiagnosticsMedtech exposureDiabetes exposureMedtechDiabetes

Products

  • Diagnostics (in vitro)
  • Glucose monitoring (Libre)
  • Medical devices & nutrition

Competitors

Risks

  • Declining covid testing
  • Broad portfolio

Same segment: Diagnostics

Tests, imaging and assays that support clinical decision-making. Segment 6 of 8 in the Medicine, pharma & life science value chain.

Compare ABT

Side by side with the largest companies in the same segment.

See where Abbott Laboratories sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.

Open the Life science value chain →